GODLY PEPTIDES
Research Intelligence
All pathways
Cellular energy & mitochondrial systems

Neurocognitive Peptide Research Pathway

Cognitive signaling and neural plasticity.

This pathway explores peptides studied for cognitive signaling, stress response, neuroprotection, and focus-related mechanisms.

System Overview

The biological system this pathway studies.

Cognitive performance and stress regulation depend on neurotrophic signaling (BDNF, NGF), synaptic plasticity, neurotransmitter systems (GABA, glutamate, monoamines), and neuroendocrine response. This pathway studies peptides that interact with these systems in models of learning, attention, mood-related signaling, and neuroprotection.

Educational research context · not medical advice

Why This Pathway Matters

Cognitive function emerges from neurotrophic signaling, plasticity, and stress regulation.

This pathway is studied to map how peptides influence BDNF-related signaling, synaptic plasticity, and neuroendocrine stress response. The work spans neuroprotection, focus-related models, and recovery of neural circuits in research settings.

Neurotrophic signaling

BDNF, NGF, and synaptic plasticity research.

Stress regulation

GABAergic and neuroendocrine modulation models.

Neuroprotection

Resilience of neurons and cognitive performance studies.

Educational research context · not medical advice

Research Progression Model

3 biological phases · click to explore

1

Research Phase 1

Cognitive Signaling

Research focus

Semax is studied for neurotrophic signaling, cognitive performance models, BDNF-related pathways, and neuroprotection research.

2

Research Phase 2

Stress Modulation

Research focus

Selank is studied for anxiolytic-like effects, stress modulation, GABA-related pathways, and immune-neuroendocrine signaling.

3

Research Phase 3

Neural Recovery

Research focus

These compounds are studied in neuroregeneration, synaptic plasticity, and cognitive function research.

Mechanism Flow

How signaling unfolds across the three research phases.

Phase 1 covers the initial biological process. Phase 2 maps the signaling cascades downstream. Phase 3 describes systemic effects studied in research models.

1

Phase 1 · Neurotrophic signaling

  • BDNF and NGF-related signaling research
  • Synaptic plasticity and neuronal survival pathways
  • Cognitive performance models in animals and small human studies
2

Phase 2 · Stress and neuromodulation

  • GABAergic and serotonergic signaling models
  • Anxiolytic-like effects in preclinical literature
  • Immune-neuroendocrine interaction studies
3

Phase 3 · Neural recovery

  • Neuroregeneration and synaptic remodeling research
  • HGF-mimetic and angiotensin-IV system studies
  • Cognitive recovery models post-injury or ischemia

Studied Compounds

Compounds studied within this pathway.

Each entry summarizes the mechanism explored in research literature. Not a recommendation, dosing guide, or protocol.

Research Observation Timeline Across This Pathway

Timeline patterns measured in studies of these compounds.

Every compound in this pathway has a primary study window described in the research literature. Windows below describe research observation periods only — not expected personal outcomes.

Emerging · 2Moderate within specific neurological contexts · 1Preclinical only · 1
  • SemaxEmerging

    Measured in studies: Days to weeks in preclinical and regional clinical studies

    Endpoint type · Gene expression, behavioral, and clinical scale endpoints

  • SelankEmerging

    Measured in studies: Days to weeks in preclinical and regional clinical contexts

    Endpoint type · Behavioral and gene expression endpoints

  • CerebrolysinModerate within specific neurological contexts

    Measured in studies: Weeks to months for functional recovery endpoints in stroke contexts

    Endpoint type · Clinical functional recovery scales and biomarker endpoints

  • DihexaPreclinical only

    Measured in studies: Days to weeks in preclinical models

    Endpoint type · Cellular and behavioral preclinical endpoints

These windows reflect research observation periods only, not guaranteed personal outcomes.

Research Insights

What current research focuses on.

  • Russian research literature accounts for much of the Semax/Selank evidence base.
  • Cerebrolysin has the largest human data set in this group, primarily in stroke and neurodegenerative settings.
  • Mechanistic plausibility (BDNF, plasticity) is stronger than translational performance data in healthy populations.

Research Limitations

Where the evidence base is incomplete.

  • Independent replication outside originating research groups is limited.
  • Long-term cognitive and safety outcomes are not well characterized.
  • Healthy-population studies are sparse compared to clinical-population data.

Transparency note · evidence gaps disclosed for research integrity

Research Relationship Overview

How these compounds are studied together.

Each phase groups compounds with mechanistic overlap. The diagram shows which compounds are explored in combination within published research literature — not a recommended use strategy.

PathwayBrain / Focus / Neur…1Phase 1Semax2Phase 2Selank3Phase 3CerebrolysinDihexa
Pathway hubResearch phaseStudied compoundMechanistic overlap
DisclaimerThis visualization reflects research relationships and does not represent a recommended use strategy. Compounds shown here are studied together in research contexts only — this is not a protocol, dosing guide, or medical advice.

For research and educational purposes only.

Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.